首站-论文投稿智能助手
典型文献
First-in-human evaluation of an independently developed Chinese robot-assisted system for percutaneous coronary intervention
文献摘要:
BACKGROUND Several studies have proved the safety and feasibility of robot-assisted percutaneous coronary intervention (PCI) in reducing the occupational hazards of interventionists while achieving precision medicine. However, an independently developed robot-assisted system for PCI in China has not yet emerged. This study aimed to evaluate the safety and feasibility of a robot-assisted system for elective PCI in China.METHODS This preclinical trial included 22 experimental pigs and preliminarily supported the safety and feasibility of the ETcath200 robot-assisted system for PCI. Then, eleven patients with coronary heart disease who met the inclusion criteria and had clinical indications for elective PCI were enrolled. PCI was performed using a robot-assisted system. The primary outcomes were clinical success (defined as visual estimated residual stenosis < 30% after PCI and no major adverse cardiovascular events during hospitalization and within 30 days after PCI) and technical success (defined as the ability to use the robot-assisted system to complete PCI successfully without conversion to the traditional manual PCI). RESULTS Eleven patients were included in this clinical trial. A drug-eluting stent with a diameter of 3 mm (interquartile range:2.75–3.5 mm) and a length of 26 mm (interquartile range: 22–28 mm) was deployed in all patients. The clinical success rate was 100%, with no PCI-related complications and no in-hospital or 30-day major adverse cardiovascular events, and the technical suc-cess rate was 100%. CONCLUSIONS The results strongly suggest that the use of the independently developed robot-assisted system in China for elective PCI is feasible, safe, and effective.
文献关键词:
作者姓名:
Guang-Yao ZHAI;Zheng CHEN;Rui-Fang LIU;Yong-He GUO;Jian-Long WANG;Tie-Nan SUN;Jing XIE;Tao HUANG;Yu-Jie ZHOU
作者机构:
Department of Cardiology,Beijing Anzhen Hospital,Capital Medical University,Beijing Institute of Heart Lung and Blood Vessel Disease,Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease,Clinical Center for Coronary Heart Disease,Capital Medical University,Beijing,China;Beijing WeMed Medical Equipment Co.,Ltd.,Beijing,China
引用格式:
[1]Guang-Yao ZHAI;Zheng CHEN;Rui-Fang LIU;Yong-He GUO;Jian-Long WANG;Tie-Nan SUN;Jing XIE;Tao HUANG;Yu-Jie ZHOU-.First-in-human evaluation of an independently developed Chinese robot-assisted system for percutaneous coronary intervention)[J].老年心脏病学杂志(英文版),2022(10):743-752
A类:
interventionists,ETcath200
B类:
First,human,evaluation,independently,developed,Chinese,robot,assisted,system,percutaneous,coronary,BACKGROUND,Several,studies,have,proved,safety,feasibility,PCI,reducing,occupational,hazards,while,achieving,precision,medicine,However,China,has,not,yet,emerged,This,study,aimed,evaluate,elective,METHODS,preclinical,trial,included,experimental,pigs,preliminarily,supported,Then,eleven,patients,heart,disease,who,inclusion,criteria,had,indications,were,enrolled,was,performed,using,primary,outcomes,defined,visual,estimated,residual,stenosis,after,major,adverse,cardiovascular,events,during,hospitalization,within,days,technical,ability,use,complete,successfully,without,conversion,traditional,manual,RESULTS,Eleven,this,drug,eluting,stent,diameter,interquartile,range,length,deployed,all,rate,related,complications,CONCLUSIONS,results,strongly,suggest,that,feasible,effective
AB值:
0.487694
相似文献
Homeopathy for COVID-19 in primary care:A randomized,double-blind,placebo-controlled trial(COVID-Simile study)
Ubiratan Cardinalli Adler;Maristela Schiabel Adler;Ana Elisa Madureira Padula;Livia Mitchiguian Hotta;Amarilys de Toledo Cesar;José Nelson Martins Diniz;Helen de Freitas Santos;Edson Zangiacomi Martinez-Department of Medicine,Federal University of S?o Carlos,S?o Carlos 13565-905,Brazil;Homeopathy Solidarity Outpatient Extension Program,Mackenzie Presbyterian University,S?o Paulo 01302-907,Brazil;Municipal Center for Integrative and Complementary Practices in Health,Guarulhos 07023-051,Brazil;HN-Cristiano Institute,S?o Paulo 02013-001,Brazil;School Health Unit,Federal University of S?o Carlos,Sao Carlos 13565-905,Brazil;Federal Institute of Education,Science and Technology of S?o Paulo,Birigui 16201-407,Brazil;Department of Social Medicine,Ribeir?o Preto Medical School,University of Sao Paulo,Ribeirao Preto 14049-900,Brazil
A trial of arbidol hydrochloride in adults with COVID-19
Zhao Jingya;Zhang Jinnong;Jin Yang;Tang Zhouping;Hu Ke;Sun Hui;Shi Mengmeng;Yang Qingyuan;Gu Peiyu;Guo Hongrong;Li Qi;Zhang Haiying;Li Chenghong;Yang Ming;Xiong Nian;Dong Xuan;Xu Juanjuan;Lin Fan;Wang Tao;Yang Chao;Huang Bo;Zhang Jingyi;Chen Shi;He Qiong;Zhou Min;Qu Jieming-Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Department of Emergency, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory and Critical Care Medicine, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Respiratory and Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, China;Department of Endocrinology, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory Medicine, Wuhan Bauhinia Hospital, Wuhan, Hubei 430062, China;Department of Respiratory Medicine, Guanggu Hospital District, The Third Hospital of Wuhan, Wuhan, Hubei 430074, China;Department of Respiratory and Critical Care Medicine, Puren Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China;Department of Respiratory Medicine, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China;Department of Respiratory Medicine, The Sixth General Hospital of Hubei Province, Wuhan, Hubei 430015, China;Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan 610066, China;Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei 430015, China;Department of Tuberculosis, Jinyintan Hospital, Wuhan, Hubei 430048, China;Department of Cardiology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。